Vaidya Sane Ayurved Laboratories Limited, operating as Madhavbaug, has launched FoodRx, a clinically designed food intervention system aimed at preventive healthcare and the management of lifestyle disorders such as diabetes, obesity, and heart disease. The initiative leverages high-protein and high-fibre traditional Indian nutrition to address the growing burden of non-communicable diseases in India. The company has treated over 10 lakh patients for these conditions over 18 years, utilizing this clinical dataset to inform the FoodRx protocols.

The FoodRx system is built on three pillars: high protein from the Indian pantry, high fibre, and traditional formats that require minimal preparation time. The program emphasizes foods like moong dal, horsegram, urad, sprouted legumes, sattu, and paneer to reduce insulin resistance and preserve lean muscle mass. Millets, oats, and pulses form the fibre core, proven to reduce HbA1c levels and improve lipid profiles.

Clinical Foundation and Expansion

Founded in 2006 by Dr. Rohit Madhav Sane, Madhavbaug has expanded from a single clinic in Khopoli, Maharashtra, to over 350 clinics and 4 hospitals across India. The company is listed on the National Stock Exchange of India. Dr. Sane established the organization following the loss of his father to a heart attack in 2004, integrating Ayurveda with modern medicine.

Key Features of FoodRx

The product is positioned for individuals at risk of metabolic disorders, such as pre-diabetics and borderline hypertensive patients, rather than those already suffering from advanced illness. Dr. Rohit Madhav Sane, Founder & MD, stated that the company has been reversing diseases for 25 years and FoodRx is an effort to ensure fewer people need reversal in the first place.

Vaidya Sane Ayurved Laboratories Limited reported its audited standalone and consolidated financial results for the year ended March 31, 2026. The company achieved a consolidated net profit of ₹8.99 crore, a 25.7% increase from ₹7.15 crore in the previous year. Revenue from operations rose by 18.9% to ₹106.91 crore, driven by sustained patient additions and the strengthening of its clinical network.

Consolidated Financial Performance

On a consolidated basis, the company reported an EBITDA of ₹15.42 crore for FY26, compared to ₹14.32 crore in FY25. Profit before tax stood at ₹10.81 crore against ₹9.90 crore in the prior year. The board approved the results at a meeting held on May 15, 2026.

Operational Highlights

For the half year ended March 31, 2026 (H2 FY26), revenue from operations grew 18.4% year-on-year to ₹56.96 crore from ₹48.12 crore in H2 FY25. Net profit for the half year was ₹4.15 crore. The company noted that while profitability was impacted by higher investments in expansion and technology, gross margins remained robust at over 82%.

Strategic Acquisition

The Board approved the acquisition of 100% shares of Parasnath Healthcare (OPC) Private Limited for a cash consideration of ₹6 crore. The target entity, focused on speciality healthcare services for knee pain and clinic operations, reported a turnover of ₹14.02 crore for FY25-26. The acquisition aims to consolidate franchisee clinic operations and strengthen the company's presence in the healthcare segment.

Outlook

Management stated that the demand for preventive and chronic care management through Ayurveda remains encouraging. By 2030, the company aims to establish 1,000 clinics, 10 hospitals, and 5,000 outpatient departments, with a focus on expanding its presence in rural India. For FY27, the company targets revenue of approximately ₹170 crore to ₹180 crore, with medium-term goals to scale revenues towards ₹250 crore to ₹300 crore by FY28 while aiming for EBITDA margins above 20%.